Purchase this article with an account.
T. Hikichi, H. Ohtsuka, M. Higuchi, T. Matsushita, H. Ariga, S. Kosaka, R. Matsushita, K. Takami; Improvement of Angiographic Findings of Polypoidal Choroidal Vasculopathy After Induction Phase of Ranibizumab Therapy. Invest. Ophthalmol. Vis. Sci. 2010;51(13):516.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To investigate the changes in angiographic findings in eyes with polypoidal choroidal vasculopathy (PCV) after one intravitreal injection of ranibizumab (0.5 mg) a month for 3 months.
Fifty consecutive eyes of 50 Japanese patients with PCV who received one intravitreal injection a month for 3 months of ranibizumab were studied prospectively. All patients were followed with fluorescein and indocyanine green angiographies using Heidelberg Retina Angiograph and optical coherence tomography. Indocyanine green angiography (ICGA) findings were compared between baseline and 1 month after the third intravitreal injection.
In the baseline ICGA, polyp lesions and abnormal choroidal vessels were seen in all eyes except two eyes in which the abnormal choroidal vessels could not be detected because of retinal and subretinal hemorrhages. One month after the third injection, ICGA showed that the polyp lesions resolved in 12 (22%) eyes, improved in 22 (44%) eyes, and were unchanged or worse in 16 (32%) eyes. In 10 (20%) eyes, the small diameter of the abnormal choroidal vessels resolved or the diameter decreased. However, the abnormal choroidal vessels were unchanged or worse in 38 (80%) eyes, and all eyes had residual abnormal choroidal vessels. The mean visual acuity (VA) improved significantly from 0.67 to 0.47 logMAR (minimum angle of resolution) (P=0.001, Wilcoxon matched-pairs signed-ranks test). No adverse events developed during the follow-up period.
Ranibizumab can improve VA and ICGA findings in eyes with PCV. Although polyp lesions tended to improve, residual abnormal choroidal vessels were present.
This PDF is available to Subscribers Only